| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
IARC, Lyon, Cedex 8, France [M. O., D. E. G., H. O., P. K., P. H.]; Cancer Genetics Unit, Royal Marsden NHS Trust, Surrey SM2 5PT, United Kingdom [N. S., R. A. E.]; and Cancer Genetics Team, Institute of Cancer Research, Surrey SM2 5NG, United Kingdom [R. A. E.]
A database has been created to collect information on families carrying a germ-line mutation in the TP53 gene and on families affected with Li-Fraumeni syndromes [Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL)]. Data from the published literature have been included. The database is available online at http://www.iarc.fr/p53, as part of the IARC TP53 Database. The analysis of the 265 families/individuals that have been included thus far has revealed several new findings. In classical LFS families with a germ-line TP53 mutation (83 families), the mean age of onset of breast cancer was significantly lower than in LFS families (16 families) without a TP53 mutation (34.6 versus 42.5 years; P = 0.0035). In individuals with a TP53 mutation, a correlation between the genotype and phenotype was found. Brain tumors were associated with missense TP53 mutations located in the DNA-binding loop that contact the minor groove of DNA (P = 0.01), whereas adrenal gland carcinomas were associated with missense mutations located in the loops opposing the protein-DNA contact surface (P = 0.003). Finally, mutations likely to result in a null phenotype (absence of the protein or loss of function) were associated with earlier onset brain tumors (P = 0.004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families.
This article has been cited by other articles:
|
|
 |
|
  V Marcel, E I Palmero, P Falagan-Lotsch, G Martel-Planche, P Ashton-Prolla, M Olivier, R R Brentani, P Hainaut, and M I Achatz TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis J. Med. Genet., November 1, 2009; 46(11): 766 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Gonzalez, K. A. Noltner, C. H. Buzin, D. Gu, C. Y. Wen-Fong, V. Q. Nguyen, J. H. Han, K. Lowstuter, J. Longmate, S. S. Sommer, et al. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations J. Clin. Oncol., March 10, 2009; 27(8): 1250 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Itahana, H. Ke, and Y. Zhang p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation J. Biol. Chem., February 20, 2009; 284(8): 5158 - 5164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Tabori and D. Malkin Risk Stratification in Cancer Predisposition Syndromes: Lessons Learned from Novel Molecular Developments in Li-Fraumeni Syndrome Cancer Res., April 1, 2008; 68(7): 2053 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Ferguson-Yates, H. Li, T. K. Dong, J. L. Hsiao, and D. H. Oh Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63 Carcinogenesis, January 1, 2008; 29(1): 70 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Malmer, P. Adatto, G. Armstrong, J. Barnholtz-Sloan, J. L. Bernstein, E. Claus, F. Davis, R. Houlston, D. Il'yasova, R. Jenkins, et al. GLIOGENE an International Consortium to Understand Familial Glioma Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1730 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Monti, Y. Ciribilli, J. Jordan, P. Menichini, D. M. Umbach, M. A. Resnick, L. Luzzatto, A. Inga, and G. Fronza Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype Clin. Cancer Res., July 1, 2007; 13(13): 3789 - 3795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Chong, H. Demirci, S. M. Ronan, A. Flint, and V. M. Elner Orbital Rhabdomyosarcoma in Li-Fraumeni Syndrome Arch Ophthalmol, April 1, 2007; 125(4): 566 - 569. [Full Text] [PDF]
|
|
|
|
|
|
L. R. Dearth, H. Qian, T. Wang, T. E. Baroni, J. Zeng, S. W. Chen, S. Y. Yi, and R. K. Brachmann Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis, February 1, 2007; 28(2): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tazawa, M. Tatemichi, T. Sawa, I. Gilibert, N. Ma, Y. Hiraku, L. A. Donehower, H. Ohgaki, S. Kawanishi, and H. Ohshima Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice Carcinogenesis, January 1, 2007; 28(1): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Valbuena, F. M. Vega, S. Blanco, and P. A. Lazo p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop. Mol. Cell. Biol., July 1, 2006; 26(13): 4782 - 4793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mizuarai, K. Yamanaka, and H. Kotani Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells. Cancer Res., June 15, 2006; 66(12): 6319 - 6326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hearle, V. Schumacher, F. H. Menko, S. Olschwang, L. A. Boardman, J. J.P. Gille, J. J. Keller, A. M. Westerman, R. J. Scott, W. Lim, et al. Frequency and spectrum of cancers in the peutz-jeghers syndrome. Clin. Cancer Res., May 15, 2006; 12(10): 3209 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Olivier, A. Langerod, P. Carrieri, J. Bergh, S. Klaar, J. Eyfjord, C. Theillet, C. Rodriguez, R. Lidereau, I. Bieche, et al. The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1157 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Ferguson and D. H. Oh Proficient Global Nucleotide Excision Repair in Human Keratinocytes but not in Fibroblasts Deficient in p53 Cancer Res., October 1, 2005; 65(19): 8723 - 8729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Hussain, G. E. Trivers, L. J. Hofseth, P. He, I. Shaikh, L. E. Mechanic, S. Doja, W. Jiang, J. Subleski, L. Shorts, et al. Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis Cancer Res., October 1, 2004; 64(19): 6849 - 6853. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
